Elective Induction at 39 Weeks (ARRIVE) — Evidence Library

What it is

In the ARRIVE trial, low-risk first-time parents were randomly assigned to induction at 39 weeks 0 days or expectant management to 40w5d. The induction group had a slightly LOWER cesarean rate (18.6% vs 22.2%) and lower rates of hypertensive disorders. There was no difference in serious newborn outcomes. Since ARRIVE, ACOG and SMFM say elective induction at 39 weeks is a reasonable option to OFFER, not a recommendation to routinely do. Real-world results depend heavily on the induction protocol used, hospital cesarean culture, and whether ripening is included.

Evidence review links

Each link opens the full review on the publisher's site in a new tab.

Possible benefits

In ARRIVE conditions, slightly lower cesarean rate and lower hypertensive-disorder rateReview sources ↓
Avoids some late-pregnancy risks (stillbirth risk rises slowly after 39 weeks)Review sources ↓
Predictable timing — helpful for logistics, support, and provider preferenceReview sources ↓

Possible risks

Longer hospital stay before birth (induction commonly takes 24–48 hours, especially for first babies)Review sources ↓
More interventions along the way (IV, continuous monitoring, epidural more likely)Review sources ↓
Trial results may not generalize to hospitals with different induction protocols or higher baseline cesarean ratesReview sources ↓
Not studied in the same way for people with prior cesareans, higher BMI, or medical conditionsReview sources ↓

Alternatives

Expectant management with monitoring until 41 or 41+3 weeksReview sources ↓
Induction only for a medical reason (hypertension, GDM, decreased movement, etc.)Review sources ↓
Membrane sweep at 39–40 weeks as a gentler first stepReview sources ↓

Current evidence

ARRIVE (NEJM 2018) is the landmark trial. ACOG/SMFM's joint statement supports offering 39-week induction to low-risk nulliparous people who prefer it, after shared decision-making. Evidence Based Birth's plain-language analysis notes that ARRIVE excluded many groups and that its induction protocol was more patient-choice-driven than many US hospitals. WHO does not recommend routine induction before 41 weeks.

Where the evidence is clear · where people may choose differently

For most topics, guidelines from ACOG, WHO, and other major bodies broadly agree on the core safety points (when to act in an emergency, informed-consent standards, monitoring baselines). Where reasonable people — and even guidelines — differ tends to be around thresholds (when to start or stop something), preferences (comfort, environment, support), and values (how you weigh small risks against benefits). Use the questions below to explore those pieces with your care team.

Educational only. Your care team can help you weigh what applies to your specific situation.